A deep learning predictive model for public health concerns and hesitancy toward the COVID-19 vaccines.

Throughout the pandemic era, COVID-19 was one of the remarkable unexpected situations over the past few years, but with the decentralization and globalization of efforts and knowledge, a successful vaccine-based control strategy was efficiently designed and applied worldwide. On the other hand, excused confusion and hesitation have widely impacted public health. This paper aims to reduce COVID-19 vaccine hesitancy taking into consideration the patient's medical history. The dataset used in this study is the Vaccine Adverse Event Reporting System (VAERS) dataset which was created as a corporation between the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) to gather reported side effects that may be caused by PFIEZER, JANSSEN, and MODERNA vaccines. In this paper, a Deep Learning (DL) model has been developed to identify the relationship between a certain type of COVID-19 vaccine (i.e. PFIEZER, JANSSEN, and MODERNA) and the adverse reactions that may occur in vaccinated patients. The adverse reactions under study are the recovery condition, possibility to be hospitalized, and death status. In the first phase of the proposed model, the dataset has been pre-proceesed, while in the second phase, the Pigeon swarm optimization algorithm is used to optimally select the most promising features that affect the performance of the proposed model. The patient's status after vaccination dataset is grouped into three target classes (Death, Hospitalized, and Recovered). In the third phase, Recurrent Neural Network (RNN) is implemented for both each vaccine type and each target class. The results show that the proposed model gives the highest accuracy scores which are 96.031% for the Death target class in the case of PFIEZER vaccination. While in JANSSEN vaccination, the Hospitalized target class has shown the highest performance with an accuracy of 94.7%. Finally, the model has the best performance for the Recovered target class in MODERNA vaccination with an accuracy of 97.794%. Based on the accuracy and the Wilcoxon Signed Rank test, we can conclude that the proposed model is promising for identifying the relationship between the side effects of COVID-19 vaccines and the patient's status after vaccination. The study displayed that certain side effects were increased in patients according to the type of COVID-19 vaccines. Side effects related to CNS and hemopoietic systems demonstrated high values in all studied COVID-19 vaccines. In the frame of precision medicine, these findings can support the medical staff to select the best COVID-19 vaccine based on the medical history of the patient.

Many-objective African vulture optimization algorithm: A novel approach for many-objective problems.

Several optimization problems can be abstracted into many-objective optimization problems (MaOPs). The key to solving MaOPs is designing an effective algorithm to balance the exploration and exploitation issues. This paper proposes a novel many-objective African vulture optimization algorithm (MaAVOA) that simulating the African vultures' foraging and navigation behaviours to solve the MaOPs. MaAVOA is an updated version of the African Vulture Optimization Algorithm (AVOA), which was recently proposed to solve the MaOPs. A new social leader vulture for the selection process is introduced and integrated into the proposed model. In addition, an environmental selection mechanism based on the alternative pool is adapted to improve the selection process to maintain diversity for approximating different parts of the whole Pareto Front (PF). The best-nondominated solutions are saved in an external Archive based on the Fitness Assignment Method (FAM) during the population evolution. FAM is based on a convergence measure that promotes convergence and a density measure that promotes variety. Also, a Reproduction of Archive Solutions (RAS) procedure is developed to improve the quality of archiving solutions. RAS has been designed to help reach out to the missing areas of the PF that the vultures easily miss. Two experiments are conducted to verify and validate the suggested MaAVOA's performance efficacy. First, MaAVOA was applied to the DTLZ functions, and its performance was compared to that of several popular many-objective algorithms and according to the results, MaAVOA outperforms the competitor algorithms in terms of inverted generational distance and hypervolume performance measures and has a beneficial adaptation ability in terms of both convergence and diversity performance measures. Also, statistical tests are implemented to demonstrate the suggested algorithm's statistical relevance. Second, MaAVOA has been applied to solve two real-life constrained engineering MaOPs applications, namely, the series-parallel system and overspeed protection for gas turbine problems. The experiments show that the suggested algorithm can tackle many-objective real-world applications and provide promising choices for decision-makers.

Deep learning in drug discovery: an integrative review and future challenges.

Recently, using artificial intelligence (AI) in drug discovery has received much attention since it significantly shortens the time and cost of developing new drugs. Deep learning (DL)-based approaches are increasingly being used in all stages of drug development as DL technology advances, and drug-related data grows. Therefore, this paper presents a systematic Literature review (SLR) that integrates the recent DL technologies and applications in drug discovery Including, drug-target interactions (DTIs), drug-drug similarity interactions (DDIs), drug sensitivity and responsiveness, and drug-side effect predictions. We present a review of more than 300 articles between 2000 and 2022. The benchmark data sets, the databases, and the evaluation measures are also presented. In addition, this paper provides an overview of how explainable AI (XAI) supports drug discovery problems. The drug dosing optimization and success stories are discussed as well. Finally, digital twining (DT) and open issues are suggested as future research challenges for drug discovery problems. Challenges to be addressed, future research directions are identified, and an extensive bibliography is also included.